TECH
Bio-Techne Corporation
Is TECH Halal?
Life sciences tools and reagents with permissible business.
What You Should Know
Bio-Techne provides biotechnology reagents, instruments and services for research and clinical diagnostics. Its March 31, 2026 Form 10-Q reports $2,550.601 million of assets, $200 million of interest-bearing debt, $209.819 million of cash, $214.562 million of receivables and $311.415 million of quarterly net sales. Debt/assets is 7.84%, liquidity/assets is 8.23%, receivables-plus-cash/assets is 16.64% and disclosed interest income is 0.32% of revenue; the examined FTSE, MSCI and Malaysia asset ratios pass, while market-cap methods remain uncalculated.
⚠️ Concerns
- •Research and diagnostic customer end uses
- •Acquisition and product-mix changes
- •Interest-bearing debt
- •Interest income
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
200 / 2,550.601
209.819 / 2,550.601
424.381 / 2,550.601
0.981 / 311.415
- Financial
- Pass
- Overall
- Pass
Debt/assets is 7.84%, liquidity/assets is 8.23%, receivables-plus-cash/assets is 16.64% and disclosed interest income is 0.32% of revenue; examined FTSE ratios and core activity pass.
- Financial
- Pass
- Overall
- Pass
Debt/assets, liquidity/assets and receivables-plus-cash/assets are below the examined MSCI total-assets limits; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Pass
Debt/assets and liquidity/assets are below the examined Malaysia limits; this is a calculation, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Bio-Techne develops and sells biotechnology reagents, instruments and services for life-science research and clinical diagnostics. The core activity is generally permissible.
Limitation: The filing does not classify every customer end use, diagnostic application or research program into a scholar-approved prohibited-revenue numerator.
Purification
Bio-Techne discloses $0.981 million of interest income, but does not provide a scholar-approved purification percentage or separate prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions converted from Bio-Techne's March 31, 2026 Form 10-Q values reported in thousands.
- Long-term debt obligations are $200 million; operating lease liabilities are excluded.
- Cash is $209.819 million. No separately identifiable interest-bearing securities are reported in the selected balance-sheet captions, so the proxy is zero.
- Accounts receivable are $214.562 million net; quarterly net sales are $311.415 million and disclosed interest income is $0.981 million.
- Bio-Techne's protein-science, diagnostics, research and life-sciences tools are generally permissible, while downstream research use remains a qualitative question.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →